Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Abstract
Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying. This review evaluates the phase III trials for all approved GLP-1 RAs and reports that all GLP-1 RAs decrease HbA1c, fasting plasma glucose, and lead to a reduction in body weight in the majority of trials. The most common adverse events are nausea and other gastrointestinal discomfort, while hypoglycaemia is rarely reported when GLP-1 RAs not are combined with sulfonylurea or insulin. Treatment options in the near future will include co-formulations of basal insulin and a GLP-1 RA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DUL is a long-acting GLP-1R agonist which can promote insulin secretion, inhibit gastric emptying, and reduce appetite. It is approved for treating hyperglycemia in patients with T2DM in many countries (105, 106).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [106]
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“reported significantly decreased postprandial plasma glucose (PPG) levels in the 5 and 10 μg exenatide groups compared with the placebo group.[15,16] In patients of Asian descent treated with oral antidiabetic agents, Gao et al.”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“respectively, and minor hypoglycemic events were less frequent in the liraglutide group than in the exenatide group.[103]”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · cited 6×
“[103] The DURATION-6 trial investigated EQW 2 mg headto-head with liraglutide 1.8 mg QD in patients treated with metformin, SU, TZD or a combination of these drugs for 26 weeks (baseline HbA1c 8.4–8.5%; BMI 32.3 kg/m2).”
BackgroundInfluentialGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 11×
“Meanwhile, the longer half-lives of the longer-acting GLP-1 RAs allow for greater effects on the total 24 h glucose level, including FPG.[6] This difference found among GLP-1 RAs is also evident in their varying efficacies with regard to HbA1c reduction and weight loss, as well as their differing tolerability profiles…”
BackgroundInfluentialKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 8×
“[103] The DURATION-6 trial investigated EQW 2 mg headto-head with liraglutide 1.8 mg QD in patients treated with metformin, SU, TZD or a combination of these drugs for 26 weeks (baseline HbA1c 8.4–8.5%; BMI 32.3 kg/m2).”
BackgroundInfluentialNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 3×
“Drucker, 2008 [72] Exenatide 2 mg QW 295 30 Met/SU/TZD or a combination −1.”
BackgroundResultGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 2×
“5%).[49,50,55] The LEAD-1 trial found liraglutide 1.”
ResultVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“treatment period of 20 weeks.[12] Exenatide BID is subcutaneously administered before the morning and evening meals as 5 μg BID for the first four weeks of”
MethodPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 1×
“[124] At present, the potential adverse effect of the increased heart rate is unknown.”
BackgroundZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · cited 2×
“0001, difference between the groups).[51] Several studies have assessed the outcome of body”
Backgroundon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · cited 1×
“0001).[52] Li and colleagues studied 90 Chinese T2DM patients on insulin therapy rando-”
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 608 · cited 2×
“[75] Several of the studies have demonstrated improvement in HOMA-B in EQW-treated patients after treated compared with at baseline.[74,76] A significant increase”
BackgroundResultPratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586 · cited 1×
“0 kg in the sitagliptin group.[58] Thus, the two studies illustrated the superiority of liraglutide to sitagliptin in terms of reducing HbA1c and weight.”
BackgroundBuse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565 · cited 1×
“SBP was lowered from the baseline in both the liraglutide and EQW groups (no difference between the groups).[104] Overall, the LEAD-6 and DURATION-6 trials found liraglutide QD to be superior to exenatide BID and EQW in terms of HbA1c and FPG, while liraglutide was only superior to EQW in terms of body weight loss.”
BackgroundAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 8×
“[93] Exenatide BID and EQW versus liraglutide QD.”
BackgroundInfluentialBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · cited 2×
“The addition of GLP-1 RA to insulin treatment has been suggested to improve glycemic control, help patients lose weight and lower the need for insulin.[22] Patients concerned about hypoglycemia may find that a GLP-1 RA in combination with metformin or an SGLT-2 inhibitor are favorable treatments.”
BackgroundPancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498 · cited 3×
“assessed by the FDA and the EMA in 2014.[117] The meta-analyses by Monami et al.”
BackgroundDungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486 · cited 1×
“HOMA-B was also assessed, and no difference was demonstrated between groups.[101]”
BackgroundVilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Self-citationNielsen, L. L., Young, A. A., & Parkes, D. G. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 457 · cited 2×
“Exenatide has a 53% amino acid overlap with native GLP-1.”
BackgroundBlevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448 · cited 2×
“Blevins, 2011 [102] Exenatide 2 mg QW 252 24 Met/SU/TZD or a combination −1.”
BackgroundNauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R., & Trautmann, M. (2007) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 437
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · cited 2×
“0001 between the groups).[73] Similar studies were conducted by Inagaki et al.”
ResultZinman, B., Hoogwerf, B. J., Durán García, S., Milton, D. R., Giaconia, J. M., Kim, D. D., Trautmann, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 427
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 1×
“preprandial hyperglycemia via the stimulation of insulin secretion, inhibition of glucagon and not the slowing of gastric emptying, as this process undergoes tachyphylaxis.[6,110,111] In contrast, the clinical effects of the”
BackgroundBunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 386
Eng, C., Kramer, C. K., Zinman, B., & Retnakaran, R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61335-0 · Cited by 383
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Gough, S. C. L., Bode, B., Woo, V., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 366
De Silva, A., Salem, V., Long, C. J., Makwana, A., Newbould, R. D., Rabiner, E. A., Ghatei, M. A., Bloom, S. R., Matthews, P. M., Beaver, J. D., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.09.010 · Cited by 353 · cited 1×
“and reduces appetite; co-agonism stimulating both the GLP-1 and PYY receptor pathways has reduced food intake in humans in preclinical studies.[136] The coagonism of several hormones may open up new treatments for T2DM and obesity.”
BackgroundMoretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350
Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V. (2014) · Diabetes Care · doi:10.2337/dc13-2759 · Cited by 341 · cited 1×
“001) after 52 weeks.[98] The AWARD-5 study was designed with a placebo-controlled period that was terminated at week 26, while the comparison of dulaglutide with sitagliptin continued (baseline HbA1c 8.”
MethodRussell-Jones, D., Cuddihy, R. M., Hanefeld, M., Kumar, A., González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 339
Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Diabetes Care · doi:10.2337/dc12-1609 · Cited by 335 · cited 1×
“short-acting agents can be explained by the lowering of postprandial hyperglycemia due to a more consistent effect on the slowing of gastric emptying.[6,112] As”
BackgroundPratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326 · cited 1×
“Pratley, 2014 [105] Albiglutide 50 mg QW 841 32 Met/SU/TZD or a combination −0.”
BackgroundMadsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., Matthews, D. R., & on behalf of the NN2211-1310 International Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1335 · Cited by 312
Self-citationCirculation and Degradation of GIP and GLP-1
Deacon, C. F. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826160 · Cited by 299
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296 · cited 2×
“[69] Biochemical risk factors such as LDL-cholesterol, free fatty acids, triglycerides, brain natriuretic peptide, plasminogen activator inhibitor-1 (PAI-1), E-selectin, high-sensitive C-reactive protein (hsCRP) and asymmetric dimethylarginine were also lowered by liraglutide treatment.”
BackgroundZinman, B., Gerich, J. E., Buse, J. B., Lewin, A., Schwartz, S. E., Raskin, P., Hale, P. M., Zdravkovic, M. D., & Blonde, L. (2010) · Diabetes Care · Cited by 290
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288 · cited 3×
“HbA1c and body weight data are presented in Table 2.[45] Taken together, the results from the current trials investigating lixisenatide versus placebo have shown better glycemic control in T2DM patients on OAD and insulin therapy via the lowering of HbA1c and FPG.”
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284
Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268 · cited 1×
“001, dulaglutide groups compared with the insulin group).[99] In the AWARD-4 study, patients (baseline”
BackgroundMeier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262 · cited 2×
“[113] The different mechanisms of action and safety profiles should be taken into consideration when electing the most appropriate treatment for a given patient.[6,114] Mealtime glucose excursions contribute to overall glycemic control and is a primary target to improve HbA1c levels.”
BackgroundBuse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care · doi:10.2337/dc14-0785 · Cited by 259 · cited 1×
“Compared with the two components separately, IDegLira decreases HbA1c significantly more.[127,128]”
MethodSeino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255 · cited 2×
“No severe hypoglycemic events occurred.[44] Riddle et al.”
BackgroundRosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Riddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253 · cited 1×
“5 Riddle-1, 2013 [46] Lixi 20 μg QD 446 24 Insulin −0.”
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237
Ahrén, B., Johnson, S. L., Stewart, M., Cirkel, D. T., Yang, F., Perry, C., & Feinglos, M. N. (2014) · Diabetes Care · doi:10.2337/dc14-0024 · Cited by 228 · cited 1×
“The weight change with placebo and sitagliptin was similar to that of with albiglutide.[87] The HARMONY-5 study”
ResultGlucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Blonde, L., Jendle, J., Gross, J., Woo, V., Jiang, H., Fahrbach, J. L., & Milicevic, Z. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60936-9 · Cited by 227 · cited 1×
“05 for both dulaglutide groups compared with the insulin group).[100] In summary, dulaglutide”
BackgroundEfficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
Self-citationRosenstock, J., Fonseca, V. A., Gross, J. L., Ratner, R. E., Ahrén, B., Chow, F. C. C., Yang, F., Miller, D., Johnson, S. L., Stewart, M. W., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0001 · Cited by 211 · cited 1×
“0001).[91] Overall, albiglutide had similar effects on HbA1c as insulin, while better FPG control was observed with insulin.”
BackgroundHerman, W. H. (2015) · Diabetes Care · doi:10.2337/dc15-1773 · Cited by 207
Madsbad, S., Kielgast, U., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01357.x · Cited by 202 · cited 3×
“[6,7,11,109] Understanding these differences is important to appropriately tailor the choice of GLP-1 RA to”
BackgroundSelf-citationUmapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193 · cited 1×
“preprandial hyperglycemia via the stimulation of insulin secretion, inhibition of glucagon and not the slowing of gastric emptying, as this process undergoes tachyphylaxis.[6,110,111] In contrast, the clinical effects of the”
BackgroundKapitza, C., Forst, T., Coester, H. ‐., Poitiers, F., Ruus, P., & Hincelin‐Méry, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12076 · Cited by 191 · cited 2×
“The different action durations largely explain the variations among GLP-1 RAs in their effects on FPG, the 24 h glucose profile, and PPG.[107,108] Delayed gastric emptying, for example, is more strongly associated with short-acting than longer-acting GLP-1 RAs; this association may underlie the greater effects on PPG…”
BackgroundJones, A. G., McDonald, T. J., Shields, B. M., Hill, A. V., Hyde, C. J., Knight, B. A., & Hattersley, A. T. (2016) · Diabetes Care · doi:10.2337/dc15-0258 · Cited by 178 · cited 1×
“In a recent ‘real-world’ study from the UK, reduced glycemic response to a GLP-1 RA was associated with a longer duration of diabetes, with insulin co-treatment and with clinical markers of low β-cell function.[113] The different mechanisms of action and safety profiles should be taken into consideration when electing…”
BackgroundAhrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172 · cited 2×
“The prevalence of hypoglycemia did not differ between the lixisenatide and placebo groups.[42,43] Pinget et al.”
BackgroundLund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 164 · cited 2×
“greater binding affinity than that of native GLP-1 at the GLP-1 receptor.[38,39] The main results are shown in Table 2.”
BackgroundGallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 159 · cited 1×
“observed in the glimepiride group.[35] Accordingly, the meta-analysis conducted by Eng et al.”
MethodMathieu, C., Rodbard, H. W., Cariou, B., Handelsman, Y., Philis‐Tsimikas, A., Ocampo Francisco, A. M., Rana, A., Zinman, B., & on behalf of the BEGIN: VICTOZA ADD‐ON (NN1250‐3948) study group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12262 · Cited by 158
Ratner, R. E., Rosenstock, J., Boka, G., & on behalf of the DRI6012 Study Investigators (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03020.x · Cited by 155
Feinglos, M. N., Saad, M. F., Pi‐Sunyer, F. X., An, B., Santiago, O., & on behalf of the Liraglutide Dose‐Response Study Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01567.x · Cited by 151
Davies, M. J., Donnelly, R., Barnett, A. H., Jones, S., Nicolay, C., & Kilcoyne, A. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01154.x · Cited by 147
The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146
Self-citationWeissman, P. N., Carr, M. C., Ye, J., Cirkel, D. T., Stewart, M. W., Perry, C., & Pratley, R. E. (2014) · Diabetologia · doi:10.1007/s00125-014-3360-3 · Cited by 145 · cited 1×
“0001 between the groups).[88] In the HARMONY-6 study, participants treated with basal insulin (baseline HbA1c 8.”
BackgroundFerdinand, K. C., White, W. B., Calhoun, D. A., Lonn, E. M., Sager, P. T., Brunelle, R., Jiang, H. H., Threlkeld, R. J., Robertson, K. E., & Geiger, M. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03062 · Cited by 145 · cited 1×
“heart rate.[69,123] The underlying mechanisms of these actions have yet to be clarified, but activation of the GLP-1 receptors in the sinoatrial node could play a role.”
BackgroundHermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143 · cited 1×
“[51,53,56,63,64] Furthermore, postprandial lipidemia (triglycerides and apolipoprotein B48) was improved during liraglutide treatment.[70] 248 L.”
BackgroundPinget, M., Goldenberg, R., Niemoeller, E., Muehlen‐Bartmer, I., Guo, H., & Aronson, R. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12121 · Cited by 139 · cited 2×
“0001, difference between the groups in both trials).[41,43] Fonseca et al.”
BackgroundDay, J. W., Gelfanov, V., Smiley, D., Carrington, P. E., Eiermann, G., Chicchi, G., Erion, M. D., Gidda, J., Thornberry, N. A., Tschöp, M. H., et al. (2012) · Peptide Science · doi:10.1002/bip.22072 · Cited by 133
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Wu, Y., Yan, P., Smith, U., Yki-Järvinen, H., Diamant, M., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.024 · Cited by 132 · cited 1×
“In three of the included studies, hypoglycemic events were significantly more common with insulin compared with exenatide treatment.[28,31,36]”
ResultRosenstock, J., Hanefeld, M., Shamanna, P., Min, K. W., Boka, G., Miossec, P., Zhou, T., Muehlen-Bartmer, I., & Ratner, R. E. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.012 · Cited by 130 · cited 4×
“The prevalence of hypoglycemia did not differ between the lixisenatide and placebo groups.[42,43] Pinget et al.”
BackgroundInfluentialEffects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.019 · Cited by 127 · cited 1×
“respectively.[21] The most common adverse events reported were nausea, vomiting, headache and diarrhea.”
BackgroundMontanya, E., & Sesti, G. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.034 · Cited by 126 · cited 1×
“Liraglutide QD Liraglutide has an amino acid sequence identity of 97% with native human GLP-1 [47] and a half-life of approximately 13 h; these qualities make liraglutide suitable for subcutaneous administration QD.”
BackgroundExenatide Versus Glibenclamide in Patients with Diabetes
Derosa, G., Maffioli, P., Salvadeo, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0141 · Cited by 125 · cited 3×
“[33,34] In the study investigating exenatide versus glibenclamide, body weight was lowered by 6.”
BackgroundResultIncretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Seino, Y., Rasmussen, M. F., Nishida, T., & Kaku, K. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003672551 · Cited by 118 · cited 2×
“0001).[56] An open-label head-to-head study with sitagliptin (100 mg/day) (baseline BMI 32.”
BackgroundSeino, Y., Rasmussen, M. F., Zdravkovic, M., & Kaku, K. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.03.018 · Cited by 117
GLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M. S., Cirincione, B. B., Maggs, D., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 113 · cited 2×
“The different action durations largely explain the variations among GLP-1 RAs in their effects on FPG, the 24 h glucose profile, and PPG.[107,108] Delayed gastric emptying, for example, is more strongly associated with short-acting than longer-acting GLP-1 RAs; this association may underlie the greater effects on PPG…”
BackgroundReusch, J., Stewart, M. W., Perkins, C. M., Cirkel, D. T., Ye, J., Perry, C. R., Reinhardt, R. R., & Bode, B. W. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12382 · Cited by 110 · cited 1×
“[85] HARMONY-2 reported an HbA1c difference of −0.”
BackgroundMonami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.010 · Cited by 106
Grunberger, G., Chang, A., Garcia Soria, G., Botros, F. T., Bsharat, R., & Milicevic, Z. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03745.x · Cited by 102
Home, P. D., Shamanna, P., Stewart, M., Yang, F., Miller, M., Perry, C., & Carr, M. C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12414 · Cited by 101
Risk of pancreatitis in patients treated with incretin-based therapies
Meier, J. J., & Nauck, M. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3231-y · Cited by 101 · cited 5×
“[26] A smaller study conducted by Bunck et al. comparing exenatide 10 µg BID and insulin glargine for 52 weeks confirmed the results of Nauck et al. and Heine et al. [30].”
ResultInfluentialDavis, S. N., Johns, D., Maggs, D. G., Xu, H., Northrup, J., & Brodows, R. G. (2007) · Diabetes Care · doi:10.2337/dc06-2532 · Cited by 99
Dirksen, C., Bojsen-Møller, K. N., Jørgensen, N. B., Jacobsen, S. H., Kristiansen, V. B., Naver, L., Hansen, D. L., Worm, D., Holst, J. J., & Madsbad, S. (2013) · Diabetologia · doi:10.1007/s00125-013-3055-1 · Cited by 98 · cited 1×
“porta and at the liver is markedly higher after surgery.[130,131] Based on this observation, the 258 L.”
BackgroundSelf-citationLeiter, L. A., Carr, M. C., Stewart, M., Jones-Leone, A., Scott, R., Yang, F., & Handelsman, Y. (2014) · Diabetes Care · doi:10.2337/dc13-2855 · Cited by 95 · cited 1×
“05 between the groups).[89] To summarize, the trials investigating albiglutide versus OAD found better 250 L.”
BackgroundInagaki, N., Atsumi, Y., Oura, T., Saito, H., & Imaoka, T. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.07.007 · Cited by 93 · cited 2×
“[75] Several of the studies have demonstrated improvement in HOMA-B in EQW-treated patients after treated compared with at baseline.[74,76] A significant increase”
ResultYang, W., Chen, L., Ji, Q., Liu, X., Ma, J., Tandon, N., Bhattacharyya, A., Kumar, A., Kim, K. ‐., Yoon, K. ‐., et al. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01323.x · Cited by 91
Gao, Y., Yoon, K., Chuang, L., Mohan, V., Ning, G., Shah, S., Jang, H. C., Wu, T.-J., Johns, D., Northrup, J., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.037 · Cited by 91
Kaku, K., Rasmussen, M. F., Clauson, P., & Seino, Y. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01194.x · Cited by 91 · cited 1×
“[69] Biochemical risk factors such as LDL-cholesterol, free fatty acids, triglycerides, brain natriuretic peptide, plasminogen activator inhibitor-1 (PAI-1), E-selectin, high-sensitive C-reactive protein (hsCRP) and asymmetric dimethylarginine were also lowered by liraglutide treatment.[51,53,56,63,64] Furthermore, po…”
BackgroundPostprandial and Basal Glucose in Type 2 Diabetes: Assessment and Respective Impacts
Monnier, L., Colette, C., & Owens, D. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0239 · Cited by 88 · cited 1×
“[115] Therefore, in patients with T2DM, reducing FPG with basal insulin and targeting mealtime glucose excursions with a short-acting GLP-1 RA may be a logical option in the treatment of patients inadequately controlled with basal insulin.”
BackgroundGallwitz, B., Böhmer, M., Segiet, T., Mölle, A., Milek, K., Becker, B., Helsberg, K., Petto, H., Peters, N., & Bachmann, O. (2011) · Diabetes Care · doi:10.2337/dc10-1900 · Cited by 88
Hjøllund, K. R., Deacon, C. F., & Holst, J. J. (2011) · Diabetologia · doi:10.1007/s00125-011-2168-7 · Cited by 84 · cited 1×
“porta and at the liver is markedly higher after surgery.[130,131] Based on this observation, the 258 L.”
BackgroundUmpierrez, G. E., Blevins, T., Rosenstock, J., Cheng, C., Anderson, J. H., Bastyr, E. J., & for the EGO Study Group (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01366.x · Cited by 84 · cited 1×
“[93–97] Three studies found a significant body weight reduction with dulaglutide compared with placebo.[93,94,97]”
BackgroundBergenstal, R., Lewin, A., Bailey, T., Chang, D., Gylvin, T., Roberts, V., & for the NovoLog Mix-vs.-Exenatide Study Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802597951 · Cited by 83 · cited 2×
“In three of the included studies, hypoglycemic events were significantly more common with insulin compared with exenatide treatment.[28,31,36]”
ResultOnce-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir
Davies, M., Heller, S., Sreenan, S., Sapin, H., Adetunji, O., Tahbaz, A., & Vora, J. (2013) · Diabetes Care · doi:10.2337/dc12-1333 · Cited by 83 · cited 2×
“0 kg, which was achieved in approximately 44% of the patients in the EQW group and 11% in the insulin group.[75] Several of the studies have demonstrated improvement in HOMA-B in EQW-treated patients after treated compared with at baseline.”
ResultHenry, R. R., Rosenstock, J., Logan, D., Alessi, T., Luskey, K., & Baron, M. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.12.009 · Cited by 80 · cited 1×
“approach in clinical phase 3 development is an osmotic minipump that continuously releases exenatide for 3–12 months after being implanted into the subcutaneous tissue.[134] Moreover, oral enhancers for GLP-1”
Backgroundde Wit, H. M., Vervoort, G., Jansen, H. J., de Grauw, W. J. C., de Galan, B. E., & Tack, C. J. (2014) · Diabetologia · doi:10.1007/s00125-014-3302-0 · Cited by 75 · cited 1×
“groups, respectively.[54] In the LEAD program, liraglutide treatment induced improvements in homeostasis model assessment of β-cell function (HOMA-B), insulin resistance”
BackgroundForst, T., Michelson, G., Ratter, F., Weber, M. M., Anders, S., Mitry, M., Wilhelm, B., & Pfützner, A. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03589.x · Cited by 75 · cited 1×
“[69] Biochemical risk factors such as LDL-cholesterol, free fatty acids, triglycerides, brain natriuretic peptide, plasminogen activator inhibitor-1 (PAI-1), E-selectin, high-sensitive C-reactive protein (hsCRP) and asymmetric dimethylarginine were also lowered by liraglutide treatment.[51,53,56,63,64] Furthermore, po…”
BackgroundLiutkus, J., Rosas Guzman, J., Norwood, P., Pop, L., Northrup, J., Cao, D., & Trautmann, M. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01251.x · Cited by 74
Derosa, G., Putignano, P., Bossi, A. C., Bonaventura, A., Querci, F., Franzetti, I., Guazzini, B., Testori, G., Fogari, E., & Maffioli, P. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.051 · Cited by 73 · cited 3×
“[33,34] In the study investigating exenatide versus glibenclamide, body weight was lowered by 6.”
BackgroundDerosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03699.x · Cited by 70
Charbonnel, B. H., Steinberg, H. O., Eymard, E., Xu, L., Thakkar, P., Prabhu, V. S., Davies, M. J., & Engel, S. S. (2013) · Diabetologia · doi:10.1007/s00125-013-2905-1 · Cited by 66 · cited 1×
“2 mg and sitagliptin groups, respectively.[60] In another study, the reduction in HbA1c after 26 weeks was −1.”
BackgroundBrady, E. M., Davies, M. J., Gray, L. J., Saeed, M. A., Smith, D., Hanif, W., & Khunti, K. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12249 · Cited by 66 · cited 1×
“needed to ensure the clinical impact of these treatment regimens, which may improve the future treatment of T2DM patients.[27,62,83]”
BackgroundLi, C.-J., Li, J., Zhang, Q.-M., Lv, L., Chen, R., Lv, C.-F., Yu, P., & Yu, D.-M. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-142 · Cited by 64
Xu, W., Bi, Y., Sun, Z., Li, J., Guo, L., Yang, T., Wu, G., Shi, L., Feng, Z., Qiu, L., et al. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12293 · Cited by 58
Incretin-based therapies: where will we be 50 years from now?
Meier, J. J., & Nauck, M. A. (2015) · Diabetologia · doi:10.1007/s00125-015-3608-6 · Cited by 57 · cited 3×
“[126] The major drawback of GLP-1 RAs is the higher cost compared with that of other antidiabetic agents.”
BackgroundInfluentialHarris, K. B., & McCarty, D. J. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814558242 · Cited by 57
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U., Holst, J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 56
Self-citationKADOWAKI, T., NAMBA, M., YAMAMURA, A., SOWA, H., WOLKA, A. M., & BRODOWS, R. G. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-296 · Cited by 52 · cited 6×
“[103] The DURATION-6 trial investigated EQW 2 mg headto-head with liraglutide 1.8 mg QD in patients treated with metformin, SU, TZD or a combination of these drugs for 26 weeks (baseline HbA1c 8.4–8.5%; BMI 32.3 kg/m2).”
BackgroundInfluentialDulaglutide: The Newest GLP-1 Receptor Agonist for the Management of Type 2 Diabetes
Thompson, A. M., & Trujillo, J. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014564180 · Cited by 51
Terauchi, Y., Satoi, Y., Takeuchi, M., & Imaoka, T. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0147 · Cited by 50
Cho, Y. M., Wideman, R. D., & Kieffer, T. J. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.4.262 · Cited by 44 · cited 3×
“[6,7,11,109] Understanding these differences is important to appropriately tailor the choice of GLP-1 RA to”
BackgroundAlbiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Blair, H. A., & Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0370-5 · Cited by 39 · cited 1×
“European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) approved albiglutide in 2014.[81,82] The main results from clinical trials for”
BackgroundComplementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 38 · cited 1×
“In addition to additive glycemic benefits, the weight loss and low hypoglycemia risk associated with GLP1RAs could at least partially offset the weight gains and risk of hypoglycemia associated with insulin use.[129] Recent trials have demonstrated the efficacy of combining insulin and GLP-1RAs in T2D.”
BackgroundTreatment of type 2 diabetes with incretin-based therapies
Madsbad, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61247-7 · Cited by 37
Self-citationSeino, Y., Inagaki, N., Miyahara, H., Okuda, I., Bush, M., Ye, J., Holland, M. C., JOHNSON, S. L., Lewis, E., & Nakajima, H. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.896327 · Cited by 32
Ueno, H., Mizuta, M., Shiiya, T., Tsuchimochi, W., Noma, K., Nakashima, N., Fujihara, M., & Nakazato, M. (2014) · Diabetes Care · doi:10.2337/dc13-0690 · Cited by 32 · cited 1×
“but these effects had a short duration.[133] Further studies are needed to evaluate the clinical potential of this form of administration.”
BackgroundHorowitz, M., Vilsbøll, T., Zdravkovic, M. D., Hammer, M., & Madsbad, S. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00861.x · Cited by 29 · cited 1×
“intestinal adverse events.[116] The issues of acute pancreatitis and pancreatic cancer in incretin-treated patients were discussed and”
BackgroundSelf-citationOnce-weekly albiglutide in the management of type 2 diabetes: patient considerations
Anderson, S. L., & Woodward, H. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s53075 · Cited by 29 · cited 1×
“European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) approved albiglutide in 2014.[81,82] The main results from clinical trials for”
BackgroundExenatide extended-release: a once weekly treatment for patients with type 2 diabetes
Raskin, P., & Mann, K. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s35331 · Cited by 26 · cited 1×
“6–7 weeks.[39,71,72] The main results of the phase 3 DURATION trials are shown in Table 4.”
BackgroundIncretin-mimetic therapies and pancreatic disease: a review of observational data
Suarez, E. A., Koro, C. E., Christian, J. B., Spector, A., de Araújo, A. B., & Abraham, S. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.960515 · Cited by 21 · cited 1×
“[120,121] A review of observational data on incretin mimetics investigating the outcome of pancreatic cancer found inconsistent results.[122] In rodent models, GLP-1 RAs have been linked with the release of calcitonin, and the potential formation of thyroid C-cell carcinoma, why it is recommended that patients with a…”
BackgroundLu, C., Wu, T.-J., Shih, K., Ni, E., Reed, V. A., Yu, M. B., Sheu, W. H., & Chuang, L. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.02.027 · Cited by 15 · cited 6×
“[103] The DURATION-6 trial investigated EQW 2 mg headto-head with liraglutide 1.8 mg QD in patients treated with metformin, SU, TZD or a combination of these drugs for 26 weeks (baseline HbA1c 8.4–8.5%; BMI 32.3 kg/m2).”
BackgroundInfluentialNauck, M. A., KREINER, E. B., Rasmussen, S., Saevereid, H. A., & Buse, J. B. (2020) · Diabetes Care · doi:10.2337/dci19-0067 · Cited by 3
Research works printed but not linked: 8
- American Diabetes Association, 2015, Diabetes Care, 38
- Lund A, 2014, Eur J Intern Med
- Robinson LE, 2013, BMJ Open, 3
- Mann KV, 2014, Diabetes Metab Syndr Obes Targets Ther, 7, 229
- Woodward HN, 2014, Patient Prefer Adherence, 8, 789
- Blair HA, 2015, Drugs
- 10.2337/dc09-0366 · DOI · Paper page
- Giorgino F, 2015, Diabetes Care
Cited by
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Mitchell, P. D., Salter, B. M., Oliveria, J. P., El‐Gammal, A., Tworek, D., Smith, S. G., Sehmi, R., Gauvreau, G. M., Butler, M., & O'Byrne, P. M. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12860 · Cited by 78
Huang, S., Ma, S.-Y., Ning, M., Yang, W., Ye, Y., Zhang, L., Shen, J., & Leng, Y. (2019) · Metabolism · doi:10.1016/j.metabol.2019.07.003 · Cited by 65
Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
Guo, W., Xu, Z., Zou, H., Li, F., Li, Y., Feng, J., Zhu, Z., Zheng, Q., Zhu, R., Wang, B., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101762 · Cited by 58
“In the last few years, dulaglutide and semaglutide have become available; these are long-acting GLP-1 analogs with >100hour half-lives and require once weekly injection [3,4].”
BackgroundWang, Q., Wang, J., Li, N., Liu, J., Zhou, J., Zhuang, P., & Chen, H. (2022) · Molecules · doi:10.3390/molecules27020444 · Cited by 63
Metadata
- Authors
- Østergaard, L., Frandsen, C. S., & Madsbad, S.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Østergaard, L.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2016-01-08
- Volume
- 9
- Issue
- 2
- Pages
- 241-265
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2220690107
- Cited by
- 38
- References
- 134
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 3 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 7 · 2016: 5
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, glucagon-like peptide-1, insulin secretion, glucagon inhibition, satiety, gastric emptying, HbA1c reduction, fasting blood glucose, weight loss, nausea, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Humans, Hypoglycemic Agents, Insulin, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.